thank and you for time to making Nichol, join us you, Thank the today. all
reasons optimistic first key objectives. are you the and made first today, in our objectives. we with executing prepare KPXXXX on the OLPRUVA launch our for second, in report During quarter, we'll access XXXX patients; to strategic quarter in X call, I'm our were and potential are steady to to these and accomplishments summary that announced program the for for first, last on earnings focused disorders. And we of arimoclomol; a successfully executing beyond. third, to the On that launch pleased report all on we we priorities: progress key and of sleep the we of ensure share
and detail, further up and HealthCare capital investors, debt capital, In key Advisors executing we new balance This credit including premier led Royalty flexibility LaDuane by biotech addition million will with refinanced provides our has mission. support our committed on strengthened $XXX in Perceptive facility, to to which our more our priorities, to added existing X Partners. in cover sheet
prioritization and The a addition become from company have X advancing is our to And rare people a companies the on significant portfolio. planning QX, making a building focus reliable talented of each growth continues long-range in flows. business to a now progress sustainable capabilities with come portfolio significant and we of cash review, period The disease transformation team of one through the work process, that including Zevra. initiated with together a with
to the initiated Achieving key at upon end and approval, our full seminal are to strategic arimoclomol that XXXX. January of successfully of inflection objectives reaching the commercial launching then, point. launch commercialize OLPRUVA OLPRUVA We
a X,XXX approximately As of build of coma approximately at U.S. is in are genetic indicated reminder, disorders, resulting brain in can urea cycle impairments, to are in potentially is ammonia disorders or certain treatment for UCDs, neurocognitive which cause group rare the levels OLPRUVA blood, of harmful the We up that a million which half in U.S. people estimate with $XXX in The market roughly annually. treated. are and, estimated and that some cases, of death. there UCD, UCD damage the or the diagnosed
it for taste it patient and well portable was phenylbutyrate. UCD personalized it Despite take. suited palatable, sodium is for formulations of associated We challenging persist. as the easy for is and that as to smell overcoming most formulated with And each unmet and requirements provides of to a living importantly, other the of therapies, needs with address availability doses people these needs patient's believe is OLPRUVA
which quarter, we we been and define our patients. our patient enrollments, demonstrating OLPRUVA we've commitment investigation Start patient benefits prescription In X of to or program. awareness UCD a focused eligible Quick on launch, as for the a Since new raising for the had
progress rare by accomplished the We that with XX more centers people that the specialists in our with the XX% disease at are of of first specialists the than excellence of encouraged launch, UCD. treat few meeting months
a assembled and professionals, also advocates, stakeholders events medical team marketers, patient engaging We've are market who of medical as and at science patient services and well as key leads access patient conferences. with
access team with care working to patients. broad has payers been ensure for managed government commercial and Our
first the OLPRUVA, the as launch more X. at we've look We May of have progress the to as launch of coverage, XX% months and in with in was forward seen growth acquired of nearly which covered the made meaningful reimbursement Overall, time reporting details lives few XX% we pleased matures. I'm to
allow a strategic we scale Zevra's with excellence. synergies us the high work given provide overlap care our and between approved, was that commercial the products will established in this proximity and arimoclomol and same realize for believe OLPRUVA majority both of fit If is patient commercial to of to within prescribers infrastructure. arimoclomol close centers footprint
our and type treat with disease NPC. team prescribers already to or begun leaders UCD Neimann-Pick identify who C, fact, and engage In and opinion compliantly has key
Our ensure with market to to payers this synergies the arimoclomol of allow These access have other will team launch therapy. our across has and patients accelerate arimoclomol. and us much-needed and requiring initiated NPC brands clinical discussions access
neurologic the be candidate rare, As potentially for progressive in U.S. treatment NPC, NPC of the development indicated arimoclomol approved, first If genetic, our treatment the a drug of is for arimoclomol in drug a reminder, disease. fatal and investigational the will
program, people expanded approximately XXX of or there in living are roughly EAP. Currently, with diagnosed. which XX approximately XXX Of those, our NPC, enrolled are access are
assigned FDA to the we at meeting which [indiscernible] resubmission the quarter, an Advisory Committee XXXX preparing. to thoroughly the for present forward XX, look for a and September we discussion of are date new PDUFA During
and submitted signatures petition Disease FDA patients, to spearheaded with X,XXX compile research was it Foundation, nearly The in National and advocacy direct QX. Neimann-Pick NPC organizations known with NNPDF, utilizing to experience arimoclomol the efforts and a physicians X of from other caregivers as
the We are community. arimoclomol overwhelmed support by for the outpouring within of
we disease. tirelessly our continue patients working maintain this review to and EAP the bring continues, will As potential this to devastating therapy living with FDA rare
on we with presentation work opinion presented leaders data clinical presentation EAP key NPC. Disorders. closely without awareness a with to stable that data, included course, was Inherited data and real-world years over We emerging raise evidence arimoclomol's to arimoclomol in had establish NPC. Metabolic defined U.S. EAP, is consistent and real-world the new Society our from observed The adults clinical profile we showing of well as XXXX, and approved, to arimoclomol, long-term, with disease intend educate study. safety of continue as from as the In that heterogeneous X April of which use, treated the patients our those foundational people profile for miglustat treatment. demonstrated II/III the The the not utilize with as for from progression If disease-modifying with disease to centers of living it including Phase to treatment
like diagnosed need people idiopathic daytime to to I'd or and Now remains need sleep being our that currently we rare, hypersomnia, IH, with IH. turn sleepiness There candidate as your sleep difficulty characterized chronic treatment KPXXXX, to for clinical with disorder. U.S. unmet a XX,XXX developed a are excessive by an waking. in the uncontrollable and estimate is attention IH
U.S. This SDX, SDX that unique overcome flexible pharmacokinetic these and receive Enforcement may ensures symptoms. dosing IV concentration you substance steadily by designated currently controlled the profile serdexmethylphenidate, drug This Drug the a was d-methylphenidate, to or ingredient. KPXXXX, as active designed allows IH primary profile to optimal in recall, active hours. for As waking patients release Schedule its is Administration.
KPXXXX During patients data in the reported of with from line study IH. quarter, we Phase II top our
by March, successfully the FDA address upcoming of need of KPXXXX tolerated large with II a in Sleep the We the look there and results. different fulfilled with completing our treatment, are presenting only the trial remains differentiated to the completed planning benefits. the objectives from meeting early We approved symptoms Since line XXXX package results, with is mechanisms informing Conference these an we've encouraged design are early study showed of reporting study which of the efficacy end-of-Phase results of that IH. QX. signs and to The meaningful full been clinically working in interpret and one sleep data June. top With to a action pivotal the community therapies the for and in unmet at trial, forward well we closely demonstrates
Assessment, Celiprolol currently the of patients impairs As hollow from our designations primary organ with is believe to conducted of Celiprolol's evaluation program muscle orphan Phase fibers [ or relaxation. for are part we connective complete off the which restarted of address approved on strategic of enrolled agreement XXX a the Special coll This patients X,XXX the treatments Celiprolol on is it within a U.S. VEDS-related with and in the unmet with in vascular protocol there drug Protocol is leads diagnosed to reduce decentralized as to mechanism that treatment designed ruptures. of preliminary a kicked the need the support for treatment being various and also reduction. III FDA.
We as to Celiprolol a is the initiative completed vascular ] planning and in we Syndrome, the event event FDA. and tissue and stress SPA, the European [ dilation trial II, January, VEDS, mechanical ] or our significant countries, received recruitment DiSCOVER for recently Vascular the the Ehlers-Danlos Celiprolol smooth program portfolio trial, preserve value known designed breakthrough collagen VEDS. and The Phase arterial while could therapy review. wall no option through under action we the
second, of of a launch Looking for to KPXXXX. and and ahead, launch have third, arimoclomol; to X of OLPRUVA; we to drive continue advance first, the prepare focus: potential outcome areas
an Now over financial provide our I'll update who will hand on to the call results. LaDuane,
